683 Capital Management LLC Grows Stock Holdings in InflaRx N.V. $IFRX

Key Points

• 683 Capital Management LLC increased its stake in InflaRx N.V. by 26.8%, now owning approximately 3.91% of the company, worth $2.68 million after acquiring an additional 555,000 shares.
• InflaRx's stock has risen 36.8%, with a current market cap of $107.41 million, and it opened at $1.60 on Tuesday, nearing its 52-week high of $2.82.
• Wall Street analysts have varied ratings on InflaRx, with a consensus rating of "Buy" and an average price target of $6.60, despite some recent downgrades.

683 Capital Management LLC lifted its position in InflaRx N.V. (NASDAQ:IFRX - Free Report) by 26.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,625,000 shares of the company's stock after buying an additional 555,000 shares during the quarter. 683 Capital Management LLC owned approximately 3.91% of InflaRx worth $2,678,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Cubist Systematic Strategies LLC lifted its stake in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. XTX Topco Ltd bought a new stake in InflaRx during the 1st quarter valued at $38,000. Geode Capital Management LLC boosted its position in InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares during the period. DAFNA Capital Management LLC bought a new stake in InflaRx in the 1st quarter worth $459,000. Finally, Northern Trust Corp increased its position in shares of InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after acquiring an additional 634,045 shares during the period. 42.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. HC Wainwright began coverage on InflaRx in a report on Tuesday, September 2nd. They set a "buy" rating and a $6.00 price target on the stock. Raymond James Financial cut shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target on the stock. in a report on Thursday, May 29th. Finally, Oppenheimer decreased their price objective on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating for the company in a report on Thursday, May 29th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $6.20.

InflaRx Trading Up 5.1%

IFRX stock traded up $0.08 during midday trading on Friday, hitting $1.65. The company's stock had a trading volume of 764,609 shares, compared to its average volume of 764,250. The company has a market cap of $110.77 million, a PE ratio of -2.06 and a beta of 1.43. The firm's 50-day moving average is $0.96 and its 200-day moving average is $1.13. InflaRx N.V. has a 12 month low of $0.71 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, hitting analysts' consensus estimates of ($0.24). The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.02 million. Analysts expect that InflaRx N.V. will post -1.04 earnings per share for the current year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.